- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.03. | Enliven Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 03.03. | Enliven Therapeutics: Q4 Earnings Insights | 1 | Benzinga.com | ||
| ENLIVEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 03.03. | Enliven Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 03.03. | Enliven Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.01. | Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars | 2 | Benzinga.com | ||
| 08.01. | Enliven Therapeutics meldet positive Phase-1b-Daten für CML-Medikament ELVN-001 | 9 | Investing.com Deutsch | ||
| 08.01. | Enliven reports positive initial phase 1b data for ELVN-001 in CML | 2 | Investing.com | ||
| 08.01. | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | 233 | PR Newswire | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| 07.01. | Enliven Therapeutics beruft Scott Garland vor entscheidender CML-Studie in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 07.01. | Scott Garland joins Enliven Therapeutics board as company prepares for CML trial | 1 | Investing.com | ||
| 07.01. | Enliven Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.12.25 | Enliven Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 11.12.25 | Enliven Therapeutics appoints Rick Fair as new CEO | 1 | Investing.com | ||
| 11.12.25 | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces New CEO to Drive Next Phase of Development | 286 | PR Newswire | Rick Fair, a seasoned executive with deep experience developing and commercializing hematology products, joins Enliven as Chief Executive Officer
Co-Founder Sam... ► Artikel lesen | |
| 11.12.25 | Enliven Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update | 250 | PR Newswire | Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML
Remains on track to initiate Phase 3 pivotal trial of ELVN-001... ► Artikel lesen | |
| 12.11.25 | Enliven Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.08.25 | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | 421 | PR Newswire | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen | |
| 13.06.25 | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress | 573 | PR Newswire | Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
| 14.05.25 | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | 707 | PR Newswire | Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June
EHA abstract reported cumulative MMR rate... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 4,630 | +2,12 % | Valneva: Nettoverlust wegen Sondereffekt vervielfacht - Lyme-Daten entscheidend | Der Impfstoffhersteller Valneva hat im Geschäftsjahr 2025 einen Nettoverlust von 115,2 Millionen Euro ausgewiesen, nach einem Verlust von 12,2 Millionen Euro im Vorjahr. Der Vergleich ist jedoch durch... ► Artikel lesen | |
| BIOFRONTERA | 2,600 | -1,89 % | Biofrontera outlines 80%-85% gross margin target for 2026 following strategic asset acquisition | ||
| CRISPR THERAPEUTICS | 40,600 | +0,50 % | Is CRISPR Therapeutics Stock a Buy Now? | ||
| DENALI THERAPEUTICS | 17,065 | -0,06 % | Denali Therapeutics Inc.: Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights | Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndromeDNL126 (ETV:SGSH) Phase 1/2 preliminary... ► Artikel lesen | |
| UNIQURE | 13,230 | +0,27 % | uniQure Inc.: uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease | LEXINGTON, Mass. and AMSTERDAM, March 02, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,957 | +3,17 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates | Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,194 | -0,93 % | Voyager Therapeutics erklärt 2026 zum "Jahr des Tau" | ||
| AGIOS | 24,400 | +0,83 % | Agios Pharmaceuticals, Inc.: Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | PYRUKYND (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full yearAQVESME (mitapivat) for thalassemia now available in U.S. following FDA approvalCompany... ► Artikel lesen | |
| CELLECTIS | 3,080 | +3,70 % | Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update | Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 populationIn target Phase 2 population: 100% of patients became eligible... ► Artikel lesen | |
| SCILEX | 7,060 | +4,44 % | Scilex Holding Company Files Federal Securities Fraud Lawsuit Seeking Recovery of Approximately Ninety-Six (96) Million Misappropriated Collateral Shares of Datavault AI, Inc. from Marc Wade, The St. James Bank & Trust Company Ltd., Omega & ... | ||
| TECTONIC THERAPEUTIC | 30,860 | 0,00 % | Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction ("PH-HFrEF")... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,230 | 0,00 % | Citizens reiterates Allogene stock rating on pipeline progress | ||
| NUVATION BIO | 4,275 | 0,00 % | Nuvation Bio Inc.: Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Successfully started 216 patients on IBTROZI® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half... ► Artikel lesen | |
| QIAGEN | 34,860 | -1,12 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen bei unverändertem Kursziel von 54 US-Dollar von "Hold" auf "Buy" hochgestuft. Analyst Jan Koch kehrt nach seiner Abstufung im Januar... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,170 | 0,00 % | Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) | New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM-304 Anticipated in 2026 Updated Phase 1/2 Data and Next... ► Artikel lesen |
Das Unternehmen ENLIVEN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 30,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENLIVEN THERAPEUTICS INC finden Sie auf Wallstreet Online.